COVID-19

IMAGE: Cryo-EM reconstructions show how two different antibodies (blue) bind to the spike protein of the SARS-CoV-2 virus.

The results of the Phase I/II trial published in the scientific journal, The Lancet, indicate no early safety concerns and induces strong immune responses in both parts of the immune system.